Therapy Areas: Cardiovascular
AstraZeneca reports Brilinta met primary endpoint in phase III THALES trial in stroke
28 January 2020 - AstraZeneca Plc (STO:AZN)(LON:SZN), a global, science-led biopharmaceutical company, announced on Monday that high-level results from the phase III THALES trial showed that the compa...
AstraZeneca divests rights to Inderal, Tenormin, Tenoretic, Zestril and Zestoretic to Atnahs for USD350m upfront
28 January 2020 - AstraZeneca Plc (STO:AZN)(LON:AZN) announced on Monday that it has agreed to sell the global commercial rights to Inderal (propranolol), Tenormin (atenolol), Tenoretic (atenolol, chl...
Moderna Receives Funding Award from CEPI to Accelerate Development of Messenger RNA Vaccine Against Novel Coronavirus
27 January 2020 - - US-based clinical stage biotechnology company Moderna, Inc., (NASDAQ: MRNA) has forged a new collaboration to develop an mRNA vaccine against the novel coronavirus (2019-nCoV), the...
European Clinical Research Centre AP-HP and IQVIA Collaborate to Launch Clinical Investigation Site
27 January 2020 - - European clinical research centre Assistance Publique Hôpitaux de Paris (AP-HP) is joining US-based health technology and human data science company IQVIA to launch the Paris...
Poxel Names Moller as Chief Scientific Officer
24 January 2020 - - French biopharmaceutical company POXEL SA has appointed David E. Moller, MD, as chief scientific officer, the company said.

Moller will be responsible for leading...
Horizon Discovery awards GS knockout CHO K1 Cell Line to NGM Bio to support research and development of biotherapeutics across therapeutic areas
22 January 2020 - Gene editing company Horizon Discovery Group plc (LSE:HZD) said on Tuesday that it has entered into an agreement to license its gene-edited Glutamine Synthetase (GS) knockout Chinese...